| Identification | Back Directory | [Name]
2-Furancarboxylic acid, 5-[3-[(2Z)-2-[1,5-dihydro-3-methyl-5-oxo-1-(5,6,7,8-tetrahydro-2-naphthalenyl)-4H-pyrazol-4-ylidene]hydrazinyl]-2-hydroxyphenyl]-, compd. with 2-aminoethanol (1:2) | [CAS]
1257792-42-9 | [Synonyms]
Hetrombopag olamine
2-Furancarboxylic acid, 5-[3-[(2Z)-2-[1,5-dihydro-3-methyl-5-oxo-1-(5,6,7,8-tetrahydro-2-naphthalenyl)-4H-pyrazol-4-ylidene]hydrazinyl]-2-hydroxyphenyl]-, compd. with 2-aminoethanol (1:2) | [Molecular Formula]
C27H29N5O6 | [MOL File]
1257792-42-9.mol | [Molecular Weight]
519.56 |
| Hazard Information | Back Directory | [Uses]
Rafutrombopag diolamine is the derivative of Rafutrombopag. Rafutrombopag is a thrombopoietin receptor agonist[1]. | [References]
[1] WHO D rug Information. EXTRAORDINARY (VIRTUAL) INTERNATIONAL CONFERENCE OF DRUG REGULATORY AUTHORITIES (ICDRA) 20-24 SEPTEMBER 2021. |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|